CLINICAL TRIALS PROFILE FOR EXELON
✉ Email this page to a colleague
All Clinical Trials for Exelon
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00000174 ↗ | Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) | Completed | Novartis | Phase 3 | 1969-12-31 | This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease (AD) in subjects taking Exelon vs. placebo. Exelon is currently under review with the U.S. Food and Drug Administration as a treatment for Alzheimer's disease. The drug has been cleared for marketing in more than 40 countries for Alzheimer's disease to date, including all 15 member states of the European Union, New Zealand, Argentina, Brazil and Mexico. Each subject with MCI will be randomly assigned to treatment with either Exelon or placebo. Subjects assigned to Exelon will receive 1.5 to 6.0 mg bid (twice daily) (3.0 to 12 mg/day) for the majority of the study. At every regular visit scheduled every three months, patients will be given basic efficacy and safety assessments. These assessments will include evaluation of adverse events, vital signs, activities of daily living, and clinical staging scales to determine if the subject may have converted to dementia. |
NCT00018278 ↗ | Electrophysiologic Measures of Treatment Response in Alzheimer Disease | Completed | US Department of Veterans Affairs | Phase 4 | 1998-10-01 | The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response. |
NCT00018278 ↗ | Electrophysiologic Measures of Treatment Response in Alzheimer Disease | Completed | VA Office of Research and Development | Phase 4 | 1998-10-01 | The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response. |
NCT00024531 ↗ | Lipitor as a Treatment for Alzheimer's Disease | Completed | Pfizer | Phase 2 | 2000-10-01 | The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease. |
NCT00024531 ↗ | Lipitor as a Treatment for Alzheimer's Disease | Completed | Institute for the Study of Aging (ISOA) | Phase 2 | 2000-10-01 | The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease. |
NCT00051909 ↗ | Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease | Completed | Eli Lilly and Company | Phase 2 | 2002-11-01 | Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon. |
NCT00105105 ↗ | Mifepristone as Adjunctive Therapy in Alzheimer's Disease | Terminated | Institute for the Study of Aging (ISOA) | Phase 2 | 2003-04-01 | The purpose of this study is to evaluate the effects of C-1073 (Mifepristone) on cognition in patients with Alzheimer's disease (AD) who are also taking an acetylcholinesterase inhibitor (Aricept, Exelon or Reminyl). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Exelon
Condition Name
Clinical Trial Locations for Exelon
Trials by Country
Clinical Trial Progress for Exelon
Clinical Trial Phase
Clinical Trial Sponsors for Exelon
Sponsor Name